NRG-GU010 / RGUP21107 / GUIDANCE / Michael Cummings
Basic Study Information
Purpose:Location: Highland Hospital
This phase III trial uses the Decipher risk score to guide intensification (for higher
Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment
to better match therapies to an individual patient's cancer aggressiveness. The Decipher
risk score evaluates a prostate cancer tumor for its potential for spreading. In patients
with low risk scores, this trial compares radiation therapy alone to the usual treatment
of radiation therapy and hormone therapy (androgen deprivation therapy). Radiation
therapy uses high energy x-rays or particles to kill tumor cells and shrink tumors.
Androgen deprivation therapy blocks the production or interferes with the action of
male sex hormones such as testosterone, which plays a role in prostate cancer development.
Giving radiation treatment alone may be the same as the usual approach in controlling
the cancer and preventing it from spreading, while avoiding the side effects associated
with hormonal therapy. In patients with higher Decipher gene risk, this trial compares
the addition of darolutamide to usual treatment radiation therapy and hormone therapy,
to usual treatment. Darolutamide blocks the actions of the androgens (e.g. testosterone)
in the tumor cells and in the body. The addition of darolutamide to the usual treatment
may better control the cancer and prevent it from spreading.
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search